• Lanabecestat (AZD3293) Experimental Workflow

  2026-08-18

  Lanabecestat (AZD3293) combines high-affinity BACE1 inhibition with a workflow designed to distinguish amyloid-beta reduction from synaptic toxicity. This guide translates reference findings into dose-ranging, dual-readout assays, troubleshooting steps, and CNS-relevant preclinical applications.

• Apicidin: HDAC Inhibitor Mechanism and Evidence

  2026-08-18

  Apicidin is a natural fungal histone deacetylase inhibitor with reported biochemical activity against HDAC3 and HDAC6. Evidence spans cancer-model tumor growth suppression, anti-angiogenesis effects, and a recent in vitro oocyte study that identifies meiotic and histone-acetylation disruption as important exposure outcomes.

• DHEA in PCOS Models: Read the Mitochondrial Signal

  2026-08-17

  Explore how Dehydroepiandrosterone (DHEA) functions as both a PCOS model inducer and a mechanistically informative steroid perturbation. This guide translates SIRT1, StAR, mitochondrial dynamics, and steroidogenesis findings into better assay design and interpretation.

• IPR-803: Urokinase Receptor Inhibitor Workflows

  2026-08-17

  IPR-803 is a small-molecule urokinase receptor inhibitor for separating uPAR–uPA signaling from general cancer-cell behavior in invasion, metastasis, and tumor-stroma studies. Its value extends from concentration-response assays in MDA-MB-231 and pancreatic cancer models to delivery-enabled combination research with gemcitabine.

• Patient-Derived Gastric Cancer Assembloids

  2026-08-16

  Shapira-Netanelov and colleagues developed patient-derived gastric cancer assembloids that combine matched tumor organoids with tumor-derived stromal subpopulations. The model reproduced key tumor–stroma interactions and revealed that stromal composition can alter transcriptional states and drug sensitivity, supporting more physiologically relevant cancer biology research and personalized screening.

• Sodium Picosulfate in Gut–Brain Assays

  2026-08-15

  Sodium Picosulfate can serve as a controlled gastrointestinal perturbation in gut–liver–brain research. This article explains how to use its defined physicochemical profile alongside regional neuroinflammation imaging without confusing bowel effects with therapeutic mechanisms.

• Catalpol Protocols for Neuroinflammation Research

  2026-08-14

  Catalpol supports mechanism-led studies that connect depressive-like behavior with oxidative stress, NLRP3 inflammasome activation, and microglial neuroinflammation. This workflow translates the CUMS mouse evidence into practical cell, tissue, behavioral, and cross-model assays while preserving clear limits on dose and interpretation.

• Protease Inhibitor Cocktail for OXPHOS Workflows

  2026-08-14

  Protect labile mitochondrial, signaling, and interaction-protein targets during cell and tissue extraction with an EDTA-free, DMSO-based formulation. This practical workflow connects protease control to LRPPRC–dasatinib OXPHOS studies, Western blotting, Co-IP, kinase assays, and tissue profiling.

• AG-490: Designing JAK2/STAT6 Assays

  2026-08-13

  AG-490 and Tyrphostin B42 can help interrogate kinase-dependent immune signaling without reducing complex exosome biology to a single inhibitor result. This guide translates recent hepatocellular carcinoma findings into a rigorous assay strategy for pathway causality, controls, and interpretation.

• GW 4869 in Lupus Nephritis Exosome Research

  2026-08-13

  GW 4869 hydrochloride hydrate provides a mechanistically grounded way to interrogate neutral sphingomyelinase-dependent exosome biology. This article connects the compound to evidence that podocyte-derived, HMGB1-rich exosomes promote glomerular endothelial injury in lupus nephritis while outlining validation strategies, translational limitations, and opportunities beyond a typical product-page description.

• Catalpol, NF-κB, and TrkB in Septic Encephalopathy

  2026-08-12

  This study shows that Catalpol mitigates LPS-induced post-sepsis cognitive impairment in mice by combining anti-inflammatory and neurotrophic effects. Its integrated behavioral, histological, pharmacokinetic, cellular, and target-engagement analyses connect NF-κB suppression with TrkB-mediated BDNF signaling, providing a mechanistic framework for neuroprotection research in septic-associated encephalopathy.

• Norovirus Co-opts NINJ1 for Selective Protein Secretion

  2026-08-12

  Song and colleagues show that murine norovirus repurposes NINJ1, a mediator of plasma membrane rupture, to release the viral protein NS1 while also permitting broad DAMP release. Their combination of CRISPR screening, infection models, protein-interaction analysis, mutagenesis, and mouse experiments defines a caspase-3-dependent secretion mechanism with physiological relevance to enteric infection.

• MYC2–LBD40/42–CRL3BPM4 Tunes Tomato Immunity

  2026-08-11

  The reference study defines a MYC2–LBD40/42–CRL3BPM4 module that balances jasmonate-dependent defense and growth in tomato challenged with Botrytis cinerea. Its central innovation is a dynamic model in which LBD40/42 act as transcriptional brakes, while BPM4-mediated degradation releases defense output when pathogen pressure requires it.

• PCN–GR Control of Hippocampal CYP and Neurotoxicity

  2026-08-11

  The 2025 reference study shows that pregnenolone 16α-carbonitrile produces opposite CYP responses in liver and hippocampus, reducing hippocampal CYP expression and phenytoin-associated neuronal injury. Its genetic and pharmacological evidence points to glucocorticoid receptor signaling, rather than PXR, as the key mediator of this brain-protective response.

• Afatinib in Gastric Cancer Assembloid Research

  2026-08-10

  Afatinib and BIBW 2992 provide a mechanistically precise way to interrogate ErbB dependence in patient-derived gastric cancer assembloids. This article explains how matched tumor–stroma models can distinguish epithelial sensitivity from microenvironment-mediated resistance.

7872 records 4/525 page Previous Next 12345 下5页 Last page